DOCSLIB.ORG

Chemoresistance in Human Ovarian Cancer: the Role of Apoptotic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chemoresistance in Human Ovarian Cancer: the Role of Apoptotic Reproductive Biology and Endocrinology BioMed Central Review Open Access Chemoresistance in human ovarian cancer: the role of apoptotic regulators Michael Fraser1, Brendan Leung1, Arezu Jahani-Asl1, Xiaojuan Yan1, Winston E Thompson2 and Benjamin K Tsang*1 Address: 1Department of Obstetrics & Gynecology and Cellular & Molecular Medicine, University of Ottawa, Ottawa Health Research Institute, Ottawa, Canada K1Y 4E9, Canada and 2Department of Obstetrics & Gynecology and Cooperative Reproductive Science Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA Email: Michael Fraser - [email protected]; Brendan Leung - [email protected]; Arezu Jahani-Asl - [email protected]; Xiaojuan Yan - [email protected]; Winston E Thompson - [email protected]; Benjamin K Tsang* - [email protected] * Corresponding author Published: 07 October 2003 Received: 26 June 2003 Accepted: 07 October 2003 Reproductive Biology and Endocrinology 2003, 1:66 This article is available from: http://www.RBEj.com/content/1/1/66 © 2003 Fraser et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Abstract Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Recent evidence suggests that deregulation of key pro- and anti-apoptotic pathways is a key factor in the onset and maintenance of chemoresistance. Furthermore, the discovery of novel interactions between these pathways suggests that chemoresistance may be multi-factorial. Ultimately, the decision of the cancer cell to live or die in response to a chemotherapeutic agent is a consequence of the overall apoptotic capacity of that cell. In this review, we discuss the biochemical pathways believed to promote cell survival and how they modulate chemosensitivity. We then conclude with some new research directions by which the fundamental mechanisms of chemoresistance can be elucidated. Ovarian Cancer and Chemoresistance: A advanced stages (stages III and IV), when the disease has Molecular and Cellular Perspective spread beyond the ovary, treatment becomes increasingly Although ovarian cancer ranks seventh among all cancers ineffective. in women in terms of prevalence, almost 60% of those who have ovarian cancer eventually succumb to the dis- Currently, the preferred treatment regimen for ovarian ease. In 2002, 23,300 new cases were identified and cancer is combination chemotherapy; usually a platinum- 13,900 deaths were reported in the United States alone. based drug, such as cisplatin or carboplatin, coupled with While breast cancer has a much higher incidence paclitaxel. While this treatment course shows promising (203,500 new cases), it has a considerably lower mortality effects in a high percentage of cases, the development of rate (39,600 deaths; approximately 20% mortality rate) chemoresistance is a hurdle that significantly hinders suc- when compared to that of ovarian cancer [1]. In fact, ovar- cessful treatment outcomes [2]. The ability of a cancer cell ian cancer causes more deaths than any other cancer of the to respond to a chemotherapeutic agent is believed to be female reproductive system. Much of the failure to obtain due, in part, to its apoptotic capacity. Moreover, it is better cure rates in ovarian cancer is a consequence of late accepted that the process of drug-induced apoptosis is diagnosis; only about 25% of patients are diagnosed governed not only by the upregulation of pro-apoptotic when the disease is still confined to the ovary. At factors or tumor suppressors, but also by modulation of Page 1 of 13 (page number not for citation purposes) Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66 cell survival factors. To that end, a number of genes ined as potential determinants of chemosensitivity. Sev- involved in either the induction or inhibition of apopto- eral such proteins are outlined below. sis, namely the p53, Akt, and phosphoinositol-3-OH- kinase (PI3K) gene families, are aberrantly regulated in X-linked inhibitor of apoptosis protein ovarian cancer [3,4]. Because of their wide-ranging bio- IAPs were first identified in baculovirus and the eukaryo- logical effects, deregulation of one or more of these factors tic homologues were subsequently characterized [9]. Cur- may give rise to a failure of drug-induced apoptosis. rently, the human IAP family includes X-linked inhibitor of apoptosis protein (Xiap), human inhibitor of apoptosis As such, a number of groups have focused their research protein (Hiap) -1 and -2, neuronal apoptosis inhibitor on elucidating the precise mechanisms by which chemo- protein (Naip), survivin and livin [10]. All IAPs contain therapeutic agents induce, and by extension fail to induce, one or more baculovirus inhibitor of apoptosis repeat apoptosis in ovarian cancer cells. We and others have (BIR) domains that block the substrate binding sites of been particularly focused on elucidating the mechanisms target caspases (Figure 1). Xiap is a 55 kDa protein, which by which several key apoptotic regulators, including p53, contains three BIR domains at the N-terminus. It requires the Inhibitor of Apoptosis (IAP) family, the Akt family, no proteolytic processing for full function and has been and the death-receptor family, may influence the response shown to have high affinity for caspases. Xiap directly of ovarian cancer cells to cisplatin. We have found that inhibits the initiator caspase-9 and execution caspase-3 aberrant regulation of these pathways plays a significant and -7. Thus, Xiap attenuates both mitochondria/cyto- role in the induction and maintenance of chemoresist- chrome c- and death receptor-mediated apoptosis [11]. ance. This review first outlines some of the major regula- Moreover, Xiap contains a C-terminus RING-Zinc finger tory pathways implicated in control of cell fate. We then domain with E3 ubiquitin ligase activity [12], which is elucidate some of the recently established interactions believed to be involved in caspase degradation via the 26S between these apoptotic regulators, and show how these proteasome. In addition, Xiap can undergo autoubiquiti- interactions are critical for chemoresistance. Finally, we nation, and Lys322 and Lys328 have recently been dem- explore some potential avenues for future work in this onstrated to be the specific sites of ubiquitin ligation to area. Xiap [13]. However, the effects of Xiap autoubiquitination on its overall function remain unclear. In addition, the The effectiveness of many of the chemotherapeutic agents Xiap mRNA contains an Internal Ribosomal Entry Site used in human cancer is highly dependent upon the abil- (IRES) element [14], which allows Xiap to be translated in ity of the cancer cell to undergo drug-induced apoptosis. a cap-independent manner during cellular stress. In con- It is now widely held that the decision to live or die in trast, non-IRES containing mRNAs are translated exclu- response to a given agent is a reflection of the overall sively in a 5' cap-dependent manner, a process that is apoptotic balance within a given cell. For example, cispla- often suspended during apoptosis due to the cleavage of tin has been shown to upregulate the pro-apoptotic fac- transcription initiation factor 4G (eIF4G) by caspase 3. tors p53, Fas, and Bax in a number of cell types [5–7]. Recently, several cellular factors have been shown to bind However, it also down-regulates specific cell survival fac- Xiap and inhibit its activity, including Xiap Associated tors such as Xiap and Akt [8]. Recent evidence suggests Factor 1 (XAF-1), Htr2A/Omi and Second Mitochondrial that chemoresistance may represent an overall imbalance Activator of Caspases (Smac or DIABLO) [15–17]. It has between these two phenomena. To that end, we and oth- been demonstrated that Smac is released from the mito- ers have long been interested in elucidating the mecha- chondria during dexamethasone-induced apoptosis in nisms of action of cisplatin in terms of its ability to multiple myeloma cells [18], further supporting the role influence these cell survival and death pathways. These of Xiap as a central molecule in cell survival. studies have identified a number of signaling pathways that are differentially regulated between chemosensitive We previously reported that cisplatin down-regulates Xiap and chemoresistant ovarian cancer cells. We will outline in chemosensitive, but not chemoresistant, ovarian cancer some of these pathways, and their potential cross-talk cells [8]. Moreover, Xiap is a determinant of chemoresist- hereafter. ance, since downregulation of Xiap in chemoresistant cells rendered the cells sensitive to the cytotoxic actions of Cell survival factors cisplatin, while overexpression of Xiap in chemosensitive While apoptosis is an important mechanism in normal cells caused a reversion to the chemoresistant phenotype development and prevention of abnormal cell growth, [8,19]. certain cellular survival factors are required to prevent inappropriate cell death. In an effort to elucidate the cel- lular mechanisms of chemoresistance in ovarian cancer, a number of novel cell survival proteins have been exam- Page 2 of 13 (page number not for citation purposes) Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/66 TheFigure Inhibitor 1 of Apoptosis Proteins
Load more

Recommended publications
  • CRKL As a Lung Cancer Oncogene and Mediator Of
    views in The spotliGhT CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to eGFR inhibitors: is it All That it is Cracked Up to Be? Marc Ladanyi summary: Cheung and colleagues demonstrate that amplified CRKL can function as a driver oncogene in lung adeno- carcinoma, activating both RAS and RAP1 to induce mitogen-activated protein kinase signaling. In addition, they show that CRKL amplification may be another mechanism for primary or acquired resistance to epidermal growth factor re- ceptor kinase inhibitors. Cancer Discovery; 1(7); 560–1. ©2011 AACR. Commentary on Cheung et al., p. 608 (1). In this issue of Cancer Discovery, Cheung and colleagues (1) mutual exclusivity. Cheung and colleagues (1) report that present extensive genomic and functional data supporting focal CRKL amplification is mutually exclusive with EGFR focal amplification of the CRKL gene at 22q11.21 as a driver mutation and EGFR amplification. However, of the 6 lung oncogene in lung adenocarcinoma. The report expands on cancer cell lines found in this study to have focal gains of data previously presented by Kim and colleagues (2). CRKL CRKL, 2 contain other major driver oncogenes (KRAS G13D is a signaling adaptor protein that contains SH2 and SH3 in HCC515, BRAF G469A in H1755; refs. 7, 8). Interestingly, domains that mediate protein–protein interactions linking both cell lines demonstrated clear dependence on CRKL in tyrosine-phosphorylated upstream signaling molecules (e.g., functional assays. Perhaps CRKL amplification is more akin BCAR1, paxillin, GAB1) to downstream effectors (e.g., C3G, to PIK3CA mutations, which often, but not always, are con- SOS) (3).
    [Show full text]
  • Evidence for an Interaction Between the Insulin Receptor and Grb7. a Role for Two of Its Binding Domains, PIR and SH2
    Oncogene (2000) 19, 2052 ± 2059 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2 Anne Kasus-Jacobi1,2,3,Ve ronique Be re ziat1,3, Dominique Perdereau1, Jean Girard1 and Anne-FrancËoise Burnol*,1 1Endocrinologie MeÂtabolisme et DeÂveloppement, CNRS, UPR 1524, 9 rue Jules Hetzel, 92190 Meudon, France The molecular adapter Grb7 is likely to be implicated in new family of adapters has recently emerged, the Grb7 the development of certain cancer types. In this study we family of proteins, comprising Grb7, Grb10 and show that Grb7 binds the insulin receptors, when they Grb14. The members of this family were originally are activated and tyrosine phosphorylated. This interac- cloned by interaction with EGF receptor, using the tion is documented by two-hybrid experiments, GST CORT (cloning of receptor target) system (Daly et al., pull-down assays and in vivo coimmunoprecipitations. In 1996; Margolis, 1994; Ooi et al., 1995), and the use of addition, our results argue in favor of a preferential the yeast two-hybrid technology has emphasized their association between Grb7 and the insulin receptors when implication in signal transduction (Daly, 1998). These compared to other tyrosine kinase receptors like the adapters bind also other tyrosine kinase receptors, like EGF receptor, the FGF receptor and Ret. Interestingly, erbB2, Ret, Elk, PDGF receptors, insulin receptors and Grb7 is not a substrate of the insulin receptor tyrosine IGF-1 receptors (Daly et al., 1996; Dey et al., 1996; kinase activity.
    [Show full text]
  • Increased in Vivo Phosphorylation of Ret Tyrosine 1062 Is a Potential Pathogenetic Mechanism of Multiple Endocrine Neoplasia Type 2B1
    [CANCER RESEARCH 61, 1426–1431, February 15, 2001] Increased in Vivo Phosphorylation of Ret Tyrosine 1062 Is a Potential Pathogenetic Mechanism of Multiple Endocrine Neoplasia Type 2B1 Domenico Salvatore, Rosa Marina Melillo, Carmen Monaco, Roberta Visconti, Gianfranco Fenzi, Giancarlo Vecchio, Alfredo Fusco, and Massimo Santoro2 Centro di Endocrinologia ed Oncologia Sperimentale del CNR, c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare [D. S., R. M. M., C. M., R. V., G. V., M. S.], and Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Facolta` di Medicina e Chirurgia [G. F.], Universita` di Napoli “Federico II,” Naples, Italy; and Dipartimento di Medicina Sperimentale e Clinica, Facolta`di Medicina e Chirurgia di Catanzaro, Universita`di Catanzaro, Catanzaro [A. F], Italy ABSTRACT are responsible for the inheritance of MEN2A and MEN2B and FMTC. Each disease has a distinct phenotype: MEN2A is associated Mutations of the Ret receptor tyrosine kinase are responsible for with MTC, pheochromocytoma, and parathyroid hyperplasia. The inheritance of multiple endocrine neoplasia (MEN2A and MEN2B) and MEN2B phenotype is more severe, being characterized by an earlier familial medullary thyroid carcinoma syndromes. Although several famil- ial medullary thyroid carcinoma and most MEN2A mutations involve occurrence of more aggressive MTC. Unlike MEN2A patients, substitutions of extracellular cysteine residues, in most MEN2B cases MEN2B patients develop multiple mucosal neuromas and several there is a methionine-to-threonine substitution at position 918 (M918T) of skeletal abnormalities. Finally, FMTC consists only of an inherited the Ret kinase domain. The mechanism by which the MEN2B mutation predisposition to MTC (3). Involvement of different tissues corre- converts Ret into a potent oncogene is poorly understood.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • And Sepsis-Induced Lung Inflammation and Mediates Myd88
    The Journal of Immunology Caveolin-1 Tyr14 Phosphorylation Induces Interaction with TLR4 in Endothelial Cells and Mediates MyD88-Dependent Signaling and Sepsis-Induced Lung Inflammation Hao Jiao,*,†,1 Yang Zhang,*,†,1 Zhibo Yan,* Zhen-Guo Wang,* Gongjian Liu,† Richard D. Minshall,*,‡ Asrar B. Malik,‡ and Guochang Hu*,‡ Activation of TLR4 by the endotoxin LPS is a critical event in the pathogenesis of Gram-negative sepsis. Caveolin-1, the signaling protein associated with caveolae, is implicated in regulating the lung inflammatory response to LPS; however, the mechanism is not understood. In this study, we investigated the role of caveolin-1 in regulating TLR4 signaling in endothelial cells. We observed that LPS interaction with CD14 in endothelial cells induced Src-dependent caveolin-1 phosphorylation at Tyr14. Using a TLR4-MD2- CD14–transfected HEK-293 cell line and caveolin-1–deficient (cav-12/2) mouse lung microvascular endothelial cells, we demon- strated that caveolin-1 phosphorylation at Tyr14 following LPS exposure induced caveolin-1 and TLR4 interaction and, thereby, TLR4 activation of MyD88, leading to NF-kB activation and generation of proinflammatory cytokines. Exogenous expression of phosphorylation-deficient Y14F caveolin-1 mutant in cav-12/2 mouse pulmonary vasculature rendered the mice resistant to LPS compared with reintroduction of wild-type caveolin-1. Thus, caveolin-1 Y14 phosphorylation was required for the interaction with TLR4 and activation of TLR4-MyD88 signaling and sepsis-induced lung inflammation. Inhibiting caveolin-1 Tyr14 phosphoryla- tion and resultant inactivation of TLR4 signaling in pulmonary vascular endothelial cells represent a novel strategy for preventing sepsis-induced lung inflammation and injury.
    [Show full text]
  • Inhibition of Mitochondrial Complex II in Neuronal Cells Triggers Unique
    www.nature.com/scientificreports OPEN Inhibition of mitochondrial complex II in neuronal cells triggers unique pathways culminating in autophagy with implications for neurodegeneration Sathyanarayanan Ranganayaki1, Neema Jamshidi2, Mohamad Aiyaz3, Santhosh‑Kumar Rashmi4, Narayanappa Gayathri4, Pulleri Kandi Harsha5, Balasundaram Padmanabhan6 & Muchukunte Mukunda Srinivas Bharath7* Mitochondrial dysfunction and neurodegeneration underlie movement disorders such as Parkinson’s disease, Huntington’s disease and Manganism among others. As a corollary, inhibition of mitochondrial complex I (CI) and complex II (CII) by toxins 1‑methyl‑4‑phenylpyridinium (MPP+) and 3‑nitropropionic acid (3‑NPA) respectively, induced degenerative changes noted in such neurodegenerative diseases. We aimed to unravel the down‑stream pathways associated with CII inhibition and compared with CI inhibition and the Manganese (Mn) neurotoxicity. Genome‑wide transcriptomics of N27 neuronal cells exposed to 3‑NPA, compared with MPP+ and Mn revealed varied transcriptomic profle. Along with mitochondrial and synaptic pathways, Autophagy was the predominant pathway diferentially regulated in the 3‑NPA model with implications for neuronal survival. This pathway was unique to 3‑NPA, as substantiated by in silico modelling of the three toxins. Morphological and biochemical validation of autophagy markers in the cell model of 3‑NPA revealed incomplete autophagy mediated by mechanistic Target of Rapamycin Complex 2 (mTORC2) pathway. Interestingly, Brain Derived Neurotrophic Factor
    [Show full text]
  • Metabolic Imaging Allows Early Prediction of Response to Vandetanib
    Metabolic Imaging Allows Early Prediction of Response to Vandetanib Martin A. Walter1,2,MatthiasR.Benz2,IsabelJ.Hildebrandt2, Rachel E. Laing2, Verena Hartung3, Robert D. Damoiseaux4, Andreas Bockisch3, Michael E. Phelps2,JohannesCzernin2, and Wolfgang A. Weber2,5 1Institute of Nuclear Medicine, University Hospital, Bern, Switzerland; 2Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; 3Institute of Nuclear Medicine, University Hospital, Essen, Germany; 4Molecular Shared Screening Resources, UCLA, Los Angeles, California; and 5Department of Nuclear Medicine, University Hospital, Freiburg, Germany The RET (rearranged-during-transfection protein) protoonco- The RET (rearranged-during-transfection protein) proto- gene triggers multiple intracellular signaling cascades regulat- oncogene, located on chromosome 10q11.2, encodes for ing cell cycle progression and cellular metabolism. We therefore a tyrosine kinase of the cadherin superfamily that activates hypothesized that metabolic imaging could allow noninvasive detection of response to the RET inhibitor vandetanib in vivo. multiple intracellular signaling cascades regulating cell sur- Methods: The effects of vandetanib treatment on the full- vival, differentiation, proliferation, migration, and chemo- genome expression and the metabolic profile were analyzed taxis (1). Gain-of-function mutations in the RET gene result in the human medullary thyroid cancer cell line TT. In vitro, tran- in uncontrolled growth and cause human cancers and scriptional changes of pathways regulating cell cycle progres- cancer syndromes, such as Hu¨rthle cell cancer, sporadic sion and glucose, dopa, and thymidine metabolism were papillary thyroid carcinoma, familial medullary thyroid correlated to the results of cell cycle analysis and the uptake of 3H-deoxyglucose, 3H-3,4-dihydroxy-L-phenylalanine, and carcinoma, and multiple endocrine neoplasia types 2A 3H-thymidine under vandetanib treatment.
    [Show full text]
  • Direct Interaction Between Calmodulin and the Grb7 RA-PH Domain
    International Journal of Molecular Sciences Article Direct Interaction between Calmodulin and the Grb7 RA-PH Domain Gabrielle M. Watson and Jacqueline A. Wilce * Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Wellington Road, Clayton VIC 3800, Australia; [email protected] * Correspondence: [email protected]; Tel.: +613-9902-9226; Fax: +613-9902-9500 Received: 7 January 2020; Accepted: 15 February 2020; Published: 17 February 2020 Abstract: Grb7 is a signalling adapter protein that engages activated receptor tyrosine kinases at cellular membranes to effect downstream pathways of cell migration, proliferation and survival. Grb7’s cellular location was shown to be regulated by the small calcium binding protein calmodulin (CaM). While evidence for a Grb7/CaM interaction is compelling, a direct interaction between CaM and purified Grb7 has not been demonstrated and quantitated. In this study we sought to determine this, and prepared pure full-length Grb7, as well as its RA-PH and SH2 subdomains, and tested for CaM binding using surface plasmon resonance. We report a direct interaction between full-length Grb7 and CaM that occurs in a calcium dependent manner. While no binding was observed to the SH2 domain alone, we observed a high micromolar affinity interaction between the Grb7 RA-PH domain and CaM, suggesting that the Grb7/CaM interaction is mediated through this region of Grb7. Together, our data support the model of a CaM interaction with Grb7 via its RA-PH domain. Keywords: Grb7; Calmodulin; RA-PH domain; SH2 domain; SPR 1. Introduction Growth receptor bound 7 (Grb7) protein is a cytoplasmic adapter protein that couples activated tyrosine kinase receptors to a nexus of downstream proliferative, migratory and survival signalling pathways [1,2].
    [Show full text]
  • GRB10 (Phospho-Ser501) Antibody
    Product Datasheet GRB10 (Phospho-Ser501) Antibody Catalog No: #12849 Package Size: #12849-1 50ul #12849-2 100ul Orders: [email protected] Support: [email protected] Description Product Name GRB10 (Phospho-Ser501) Antibody Host Species Rabbit Clonality Polyclonal Applications WB Species Reactivity Hu Ms Rt Specificity Phospho-GRB10 (S501) Antibody detects endogenous levels of GRB10 only when phosphorylated at S501 Immunogen Type Peptide-KLH Immunogen Description A synthesized peptide derived from human GRB10 (Phospho-Ser501) Other Names grb 10 antibody GRB IR antibody grb-10 antibody GRB10 adapter protein antibody GRB10 adaptor protein antibody GRB10 antibody GRB10_HUMAN antibody GRBIR antibody Growth factor receptor bound protein 10 antibody Growth factor receptor-bound protein 10 antibody Insulin receptor binding protein antibody Insulin receptor binding protein GRB IR antibody Insulin receptor-binding protein Grb-IR antibody IRBP antibody KIAA0207 antibody Maternally expressed gene 1 antibody MEG1 antibody RSS antibody Accession No. Swiss-Prot#:Q13322 NCBI Gene ID2887 Calculated MW 76 Concentration 1.0mg mL Formulation Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+) pH 7.4 150mM NaCl 0.02% sodium azide and 50% glycerol. Storage Store at -20°C Application Details WB dilution:1:1000 Images Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 1 Western blot analysis GRB10 (Phospho-Ser501) using EGF treated HeLa whole cell lysates Product Description Recently GRB10 was shown to be a direct substrate of mTORC1 (5). It is phosphorylated by mTORC1 at Ser150, Ser428, and Ser476 upon insulin stimulation (5).The GRB7 family of adaptor proteins consist of GRB7, GRB10 and GRB14, which all contain an amino-terminal proline-rich SH3 binding domain, followed by PH, PBS, and SH2 domains.
    [Show full text]
  • Grb7, a Critical Mediator of EGFR/Erbb Signaling, in Cancer Development and As a Potential Therapeutic Target
    cells Review Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target 1, 1,2, 1,3, Pei-Yu Chu y , Yu-Ling Tai y and Tang-Long Shen * 1 Department of Plant Pathology and Microbiology, National Taiwan University, Taipei 10617, Taiwan; [email protected] (P.-Y.C.); [email protected] (Y.-L.T.) 2 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3 Center for Biotechnology, National Taiwan University, Taipei 10617, Taiwan * Correspondence: [email protected]; Tel.: +886-2-3366-4998 These authors contributed equally to this work. y Received: 30 March 2019; Accepted: 9 May 2019; Published: 10 May 2019 Abstract: The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. In particular, critical roles of Grb7 in erythroblastic leukemia viral oncogene homolog (ERBB) family-mediated cancer development and malignancy have been intensively evaluated. The overexpression of Grb7 or the coamplification/cooverexpression of Grb7 and members of the ERBB family play essential roles in advanced human cancers and are associated with decreased survival and recurrence of cancers, emphasizing Grb70s value as a prognostic marker and a therapeutic target. Peptide inhibitors of Grb7 are being tested in preclinical trials for their possible therapeutic effects. Here, we review the molecular, functional, and clinical aspects of Grb7 in ERBB family-mediated cancer development and malignancy with the aim to reveal alternative and effective therapeutic strategies.
    [Show full text]
  • The Phosphorylation of Ephb2 Receptor Regulates Migration and Invasion of Human Glioma Cells
    [CANCER RESEARCH 64, 3179–3185, May 1, 2004] The Phosphorylation of EphB2 Receptor Regulates Migration and Invasion of Human Glioma Cells Mitsutoshi Nakada,1,2 Jared A. Niska,2 Hisashi Miyamori,3 Wendy S. McDonough,2 Jie Wu,1 Hiroshi Sato,3 and Michael E. Berens2 1Neuro-Oncology Research, Barrow Neurological Institute, Phoenix, Arizona; 2The Translational Genomics Research Institute, Phoenix, Arizona; and 3Department of Molecular Virology and Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan ABSTRACT logical functions have been attributed to Eph receptors and ephrins, including vascular development, tissue-border formation, cell migra- Eph receptor tyrosine kinases and their ligands, ephrins, mediate neu- tion, axon guidance, and synaptic plasticity (4–7). rodevelopmental processes such as boundary formation, axon guidance, There is increasing evidence that the B-family of Eph receptors and vasculogenesis, and cell migration. We determined the expression profiles of the Eph family members in five glioma cell lines under migrating and ephrins are functionally involved in the organization of the central nonmigrating conditions. EphB2 mRNA was overexpressed in all five nervous system during development (3, 4). EphB–ephrin-B signaling during migration (1.2–2.8-fold). We found abundant EphB2 protein as is critical for establishing boundaries between segments of the verte- well as strong phosphorylation of EphB2 in migrating U87 cells. Confocal brate hindbrain (8). Early-migrating EphB2-expressing neural crest imaging showed EphB2 localized in lamellipodia of motile U87 cells. cells are repelled by ephrin-B ligands expressed in the caudal somatic Treatment with ephrin-B1/Fc chimera stimulated migration and invasion compartment (9, 10).
    [Show full text]
  • Eph Receptor Signalling: from Catalytic to Non-Catalytic Functions
    Oncogene (2019) 38:6567–6584 https://doi.org/10.1038/s41388-019-0931-2 REVIEW ARTICLE Eph receptor signalling: from catalytic to non-catalytic functions 1,2 1,2 3 1,2 1,2 Lung-Yu Liang ● Onisha Patel ● Peter W. Janes ● James M. Murphy ● Isabelle S. Lucet Received: 20 March 2019 / Revised: 23 July 2019 / Accepted: 24 July 2019 / Published online: 12 August 2019 © The Author(s) 2019. This article is published with open access Abstract Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that 1234567890();,: 1234567890();,: drive Eph receptor signalling, and investigates the contribution of intra- and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6.
    [Show full text]